Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.

Clinical and experimental medicine - 31 May 2026

Li Man, Wang Xiao, Li Pengen, Gong Hongjie, Wu Jianbing, Mao Ye

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive gastrointestinal cancers, with over 90% of cases harboring KRAS gene mutations. These mutations not only serve as key drivers of tumorigenesis but also reshape the tumor microenvironment (TME), creating a highly immunosuppressive "cold tumor" characterized by immune cell dysfunction, a dense fibrotic stroma, and a unique metabolic state. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Mutation

Share to Oncogene Protein p21(ras)

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 42218726
DOI: 10.1007/s10238-026-02201-8
PMCID: PMC13433729

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.PMID 42218726Read ↗

Emerging Treatment Strategies in Pancreatic Cancer.Semantic proximity Read ↗

Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC ModelSemantic proximity Read ↗

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read ↗

Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospectsSemantic proximity Read ↗

The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.Semantic proximity Read ↗

A Young Scientist's Guide to PDAC: Past, Present, and FutureSemantic proximity Read ↗

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here.Semantic proximity Read ↗

New therapeutic targets in pancreatic cancer.Semantic proximity Read ↗

Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockadeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.